Literature DB >> 21239996

Systemic and mucosal differences in HIV burden, immune, and therapeutic responses.

Sharon M Wahl1, Maryann Redford, Shawna Christensen, Wendy Mack, Jon Cohn, Edward N Janoff, Jiri Mestecky, Hal B Jenson, Mahvash Navazesh, Mardge Cohen, Patricia Reichelderfer, Andrea Kovacs.   

Abstract

BACKGROUND: Mucosal tissues represent major targets for HIV transmission but differ in susceptibility and reservoir function by unknown mechanisms.
METHODS: In a cross-sectional study, HIV RNA and infectious virus were compared between oral and genital compartments and blood in HIV-infected women, in association with clinical parameters, copathogens, and putative innate and adaptive HIV inhibitors.
RESULTS: HIV RNA was detectable in 24.5% of women from all 3 compartments, whereas 45% had RNA in only 1 or 2 sites. By comparison, infectious HIV, present in blood of the majority, was rare in mucosal sites. Innate mediators, secretory leukocyte protease inhibitor and thrombospondin, were highest in mucosae. Highly active antiretroviral therapy was associated with an 80% decreased probability of shedding. Multivariate logistic regression models revealed that mucosal HIV RNA was associated with higher plasma RNA, infectious virus, and total mucosal IgA, but not IgG. There was a 37-fold increased probability of detecting RNA in both genital and oral specimens (P = 0.008; P = 0.02, respectively) among women in highest versus lowest IgA tertiles.
CONCLUSIONS: Mucosal sites exhibit distinct characteristics of infectious HIV, viral shedding, and responses to therapy, dependent upon both systemic and local factors. Of the putative innate and adaptive mucosal defense factors examined, only IgA was associated with HIV RNA shedding. However, rather than being protective, there was a striking increase in probability of detectable HIV RNA shedding in women with highest total IgA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239996      PMCID: PMC3164950          DOI: 10.1097/QAI.0b013e31820cdfdb

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  50 in total

1.  Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI.

Authors:  Weifeng Xu; Bing He; April Chiu; Amy Chadburn; Meimei Shan; Malwina Buldys; Aihao Ding; Daniel M Knowles; Paul A Santini; Andrea Cerutti
Journal:  Nat Immunol       Date:  2007-01-28       Impact factor: 25.606

Review 2.  HIV accomplices and adversaries in macrophage infection.

Authors:  Sharon M Wahl; Teresa Greenwell-Wild; Nancy Vázquez
Journal:  J Leukoc Biol       Date:  2006-08-14       Impact factor: 4.962

3.  Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.

Authors:  N K Jana; L R Gray; D C Shugars
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Authors:  Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

5.  Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.

Authors:  Alison Wright; Michael E Lamm; Yung T Huang
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

6.  HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers.

Authors:  Taha Hirbod; Rupert Kaul; Camilla Reichard; Joshua Kimani; Elizabeth Ngugi; Job J Bwayo; Nico Nagelkerke; Klara Hasselrot; Bing Li; Stephen Moses; Kelly S MacDonald; Kristina Broliden
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

7.  Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.

Authors:  Nicolas Chomont; Hakim Hocini; Jean-Chrysostome Gody; Hicham Bouhlal; Pierre Becquart; Corinne Krief-Bouillet; Michel Kazatchkine; Laurent Bélec
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

Review 8.  Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.

Authors:  Kimberly A Powers; Charles Poole; Audrey E Pettifor; Myron S Cohen
Journal:  Lancet Infect Dis       Date:  2008-08-04       Impact factor: 25.071

9.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Authors:  David I Watkins; Dennis R Burton; Esper G Kallas; John P Moore; Wayne C Koff
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

Review 10.  Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease.

Authors:  Susan Moir; Anthony S Fauci
Journal:  J Allergy Clin Immunol       Date:  2008-06-10       Impact factor: 10.793

View more
  4 in total

Review 1.  Tissue reservoirs of HIV.

Authors:  Joseph K Wong; Steven A Yukl
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

2.  Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples.

Authors:  Robert Y Choi; Pauline Levinson; Brandon L Guthrie; Barbara Lohman-Payne; Rose Bosire; Amy Y Liu; Taha Hirbod; James Kiarie; Julie Overbaugh; Grace John-Stewart; Kristina Broliden; Carey Farquhar
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

3.  Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.

Authors:  Sara Moron-Lopez; Guorui Xie; Peggy Kim; David A Siegel; Sulggi Lee; Joseph K Wong; Jennifer C Price; Najwa Elnachef; Ruth M Greenblatt; Phyllis C Tien; Nadia R Roan; Steven A Yukl
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 5.396

4.  HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.

Authors:  Rami Kantor; Daniel Bettendorf; Ronald J Bosch; Marita Mann; David Katzenstein; Susan Cu-Uvin; Richard D'Aquila; Lisa Frenkel; Susan Fiscus; Robert Coombs
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.